Group items tagged

This funding opportunity announcement (FOA) seeks Research Project Grant (R01) applications that propose to use a common conceptual model to develop behavioral interventions to modify health behaviors and improve health outcomes in patients with comorbid chronic diseases and health conditions. Specifically, this FOA will support research in primary care that uses a multi-disease care management approach to behavioral interventions with high potential impact to improve patient-level health outcomes for individuals with three or more chronic health conditions. The proposed approach must modify behaviors using a common approach rather than administering a distinct intervention for each targeted behavior and/or condition. Diseases and health conditions can include, but are not limited to: mental health disorders (e.g., depression), diabetes, smoking, obesity, chronic pain, alcohol and substance abuse and dependence, chronic obstructive pulmonary disorder, cancer and hypertension.

This Funding Opportunity Announcement (FOA) encourages R21 research grant applications from institutions/organizations that propose to investigate whether, and how, heavy involvement in new digital media usage, particularly social media and social networking sites, may influence adolescent alcohol use and drinking patterns, as well as drinking-related problems. This FOA also encourages applications proposing to explore the ways in which new digital media may be utilized as platforms for preventive interventions aimed at underage drinking and related problems. 

This Funding Opportunity Announcement (FOA) encourages R01 research grant applications from institutions/organizations that propose to investigate whether, and how, heavy involvement in new digital media usage, particularly social media and social networking sites, may influence adolescent alcohol use and drinking patterns, as well as drinking-related problems. This FOA also encourages applications proposing to explore the ways in which new digital media may be utilized as platforms for preventive interventions aimed at underage drinking and related problems.

This Funding Opportunity Announcement (FOA) seeks to stimulate and expand research on the interplay of genetic and environmental factors in the genesis, course, and outcomes of substance and alcohol use disorders (SUDs). Previous work in genetic epidemiology and molecular genetics has established that SUDs are highly heritable, developmental disorders with important genetic substrates.  Building on these findings, new studies using genetically informative approaches are needed to elucidate the complex interplay of genetic and environmental factors in developmental trajectories of SUDs and comorbid conditions, deepen and refine phenotypic definitions of SUDs, and meet the methodologic challenges of the field.  Such studies hold great potential to promote understanding of the true contributions of both genetic and environmental factors to initiation, progression, comorbidity, adverse outcomes, and cessation of SUDs; to elucidate mechanisms of risk; and to enhance opportunities for translation to treatment, prevention, gene-finding and molecular studies. 

The purpose of this program is to provide funding to states to enhance/expand their treatment service systems to increase capacity and provide accessible, effective, comprehensive, coordinated care, and evidence-based medication assisted treatment (MAT) and recovery support services to individuals with opioid use disorders seeking or receiving MAT. As a result of this program, SAMHSA seeks to: 1) increase the number of individuals receiving MAT services with pharmacotherapies approved by the FDA for the treatment of opioid use disorders; 2) increase the number of individuals receiving integrated care; and 3) decrease illicit drug use at 6-months follow-up. For the purpose of this RFA, integrated care is defined as the organized delivery and/or coordination of medical, behavioral or social and recovery support services provided to individual patients in order to produce better overall health outcomes for people that may have multiple healthcare needs. MAT is defined as the use of FDA-approved opioid agonist medications (e.g., methadone, buprenorphine products including buprenorphine/naloxone combination formulations and buprenorphine mono-product formulations) for the maintenance treatment of opioid use disorder and opioid antagonist medication (e.g., naltrexone products including extended-release and oral formulations) to prevent relapse to opioid use. MAT includes screening, assessment (which includes determination of severity of opioid use disorder, including presence of physical dependence and appropriateness for MAT) and case management. MAT is to be provided in combination with comprehensive substance use disorder treatment, including but not limited to: counseling, behavioral therapies and when needed pharmacotherapy for co-occurring alcohol use disorder. MAT is to be provided in a clinically driven, person-centered and individualized setting. Priority will be given to states (listed in Appendix V) that have not only demonstrated a high rate of primary treatme

There are 5.4 million individuals who self-identify as American Indian/Alaska Native (AI/AN) in the US, and there are 567 federally registered tribes. While characterized by many strengths and resiliencies, as a whole, AI/AN populations experience significant disparities compared to the general population across a range of health conditions and outcomes, including infant mortality, alcohol-related mortality, substance abuse, unintentional injury, homicide, suicide, depression, post-traumatic stress disorder, obesity, chronic kidney disease, asthma, diabetes, cardiovascular disease, selected cancers, and other chronic diseases. Premature death rates, while decreasing in other US racial/ethnic minority populations over the past 15 years, are increasing among AI/AN populations. However, the examination of data on AI/AN populations in aggregate may obscure the significant heterogeneity within the AI/AN population due to tribal affiliation, geographic region, and other factors. For example, gastric cancers affect AI/AN populations in different parts of the country at different rates ranging from 6.1/100,00 in the Eastern US to 24.5/100,000 in Alaska. At the same time, national survey and epidemiological studies often do not report data on AI/AN populations because the numbers are too small or AI/AN individuals are folded into the highly heterogeneous "Other" category, thus not available to interpret any health outcomes specific for AI/AN populations. For these reasons, there is a critical need to build a more comprehensive evidence base regarding the health of AI/AN populations.

NIDA and the following NIH Institutes, Centers, and Programs, NIAAA, NICHD, NIMH, NIMHD, NINDS, and ECHO intend to publish a funding opportunity announcement to solicit applications to propose and test the feasibility of research study designs addressing the impact of pre- and postnatal substance exposure (including opioids, opioid treatment medications, cannabis, alcohol, tobacco, other prescription or illicit substances, alone or in combination) on brain, social, and behavioral development, mental illness, and substance use. In addition to planning and testing the feasibility of study designs, awardees will be expected to participate in several grantee meetings to share lessons learned and begin to develop the network of sites needed to conduct this study.

To that end, the foundation awards grants to organizations and programs that advance the prevention, diagnosis, and treatment of alcoholism, chemical dependency, and addictive behavior, including support for related research and education.

This Funding Opportunity Announcement (FOA) encourages Small Business Technology Transfer (STTR) applications from small business concerns (SBCs) that propose the development of therapeutic agents for disorders that fall under the mission of NIAAA.  An identified candidate, having sufficient bioactivity, stability, manufacturability, bioavailability, in vivo efficacy and/or target engagement, and other favorable properties that are consistent with the desired clinical application, is required prior to application. The FOA supports Investigational New Drug (IND)-enabling studies for the therapeutic candidate. At the end of the funding period, a successful project should have, at a minimum, an IND application submitted to the U.S. Food and Drug Administration (FDA). The program supports early-phase clinical trials, although these are not required. Also listed under U44

The purpose of this program is to make grants to the 50 states, the District of Columbia, and the U.S. Territories to assist them in operating their own state educational loan repayment programs for primary care providers working in HPSAs within their state. SLRP supports loan repayment awards to health care providers in exchange for service in underserved communities. SLRP recipients are afforded the flexibility to select the disciplines and HPSA sites that meet their unique workforce needs. To that end, HRSA is encouraging SLRP applicants to consider how SLRP funds might be used to support the clinical priorities of addressing opioid abuse and mental health conditions. Please note, this NOFO expands the disciplines supported by SLRP to include Masters-level, licensed alcohol and substance abuse counselors.

This Funding Opportunity Announcement (FOA) solicits applications to continue the International epidemiology Databases to Evaluate AIDS (IeDEA) Program. The IeDEA program is comprised of 7 regional data center awards, which bring together clinical and research data within regions, and in collaboration monitor and guide the response to the HIV/AIDS epidemic. This research includes work on the long-term impact of HIV and its treatment, the epidemiology of common co-infections (e.g., hepatitis and tuberculosis). Research also evaluates health care utilization including medications, procedures, and vaccines, studies of co-morbidities such as cancer, disruption of physiological and metabolic processes leading to end organ impairment, mental health and alcohol and substance use. Data sources include clinical care, surveillance or research protocols as well as a Sentinel Research Network which collects data in a more intensive prospective cohort to understand the impact of non-communicable disease in HIV and allow for inferences across the network. This funding announcement also asks IeDEA to include a cohort of persons with tuberculosis (TB) to evaluate TB treatment outcomes. IeDEA facilitates access to data working with data consumers at the clinic, national, and global level and creating data tools.

This Funding Opportunity Announcement (FOA) seeks to stimulate and expand research on the interplay of genetic and environmental factors in the genesis, course, and outcomes of substance and alcohol use disorders (SUDs). Previous work in genetic epidemiology and molecular genetics has established that SUDs are highly heritable, developmental disorders with important genetic substrates.Building on these findings, new studies using genetically informative approaches are needed to elucidate the complex interplay of genetic and environmental factors in developmental trajectories of SUDs and comorbid conditions, deepen and refine phenotypic definitions of SUDs, and meet the methodologic challenges of the field.Such studies hold great potential to promote understanding of the true contributions of both genetic and environmental factors to initiation, progression, comorbidity, adverse outcomes, and cessation of SUDs; to elucidate mechanisms of risk; and to enhance opportunities for translation to treatment, prevention, gene-finding and molecular studies.

The objectives of this research are to 1. Define and quantify the health and safety issues facing public transit workers. These include, but are not limited to, behaviors that affect health and safety (sleep, exercise, diet, smoking, seat belt use, alcohol use), chronic diseases (diabetes, cardio-vascular disease, hearing loss), communicable diseases, labor environment, organizational issues (safety climate, organizational programs, policies and procedures, support at work), organization of work (shiftwork, job discretion, job demands), and access to health-promoting activities and healthcare; 2. Using existing information resources, estimate the costs associated with employee health issues; and characterize to the degree possible how these costs are distributed to individuals, transit agencies, and society; 3. Identify and describe scalable and sustainable strategies successfully implemented in transit agencies; and 4. Identify and evaluate potential methods for measuring cost-benefits and cost-effectiveness of these programs to individuals, transit agencies, and society.

The purpose of this Funding Opportunity Announcement (FOA) is to provide support for the development of innovative interventions that improve cancer-related health behaviors across diverse racial/ethnic populations. Specifically, this FOA is intended to stimulate research aimed at 1) testing new theories and conceptual frameworks; 2) developing and evaluating novel strategies to improve cancer-related health behaviors; 3) investigating multi-level and multi-behavioral approaches; and 4) utilizing innovative research designs, methodologies, and technologies. The cancer-related health behaviors to be targeted are diet, obesity, physical activity and sedentary behavior, smoking, sleep and circadian dysfunction, alcohol use, and/or adherence to cancer-related medical regimens. Research can involve any aspect of the cancer continuum and any phase of the translational spectrum.

The purpose of this funding opportunity announcement (FOA) is to encourage exploratory developmental research to improve Native American (NA) health. Such research can include: conducting secondary analysis of existing data (such as databases that the Tribal Epidemiology Centers have collected); merge various sources of data to answer critical research questions; conduct pilot and feasibility studies; and/or assess and validate measures that are being developed and/or adapted for use in NA communities. For the purposes of this FOA, the term 'Native Americans' includes the following populations: Alaska Native, American Indian, and Native Hawaiian. The term 'Native Hawaiian' means any individual whose ancestors were natives, prior to 1778, belonging to the area that now comprises the State of Hawaii. Studies should: be culturally appropriate and result in promoting the adoption of healthy lifestyles; improve behaviors and social conditions and/or improve environmental conditions related to chronic disease; prevent or reduce the consumption of tobacco, alcohol, and other drugs; improve mental health outcomes; reduce risk of HIV infection; improve treatment adherence and/or health-care systems adopting standards of care to improve overall quality of life.

  NIDA is interested in research that addresses research gaps related to PrEP and its use among substance users, with the goals of improving PrEP management and implementation. Current US Public Health Service PrEP guidelines recommend PrEP for people who inject drugs (PWID) and mention alcohol and illicit drug use as potential concerns for clinical management. Only one clinical trial has evaluated PrEP among PWID and systematic data regarding the broader use of PrEP among substance users are limited. There is a need to better understand the effects of substance use on PrEP effectiveness and better inform PrEP implementation among substance users. More systematic data are needed regarding the impact of substance use on PrEP management and adherence, along with investigating potential unintended consequences of PrEP use that may be unique to substance users such as changes in harm reduction practices, as well as substance use as a contributor to health risk behaviors with consequences such as increased occurrence of STIs.

This initiative will fund the dissemination and implementation of clinical and organizational patient-centered outcomes research (PCOR) findings into primary care practice to improve the delivery of patient-centered approaches to identifying and managing

NIAAA is seeking applications for medications development research projects from both for-profit and not-for-profit entities, including academic institutions, pharmaceutical and biotechnology companies, private and public foundations, small businesses not eligible for the SBIR/STTR program and single entities able to demonstrate significant resource commitment to the proposed project. A resource commitment from a single entity could, for example, consist of salary support for key personnel or production and formulation of clinical trial material.

The SBIR program, as established by law, is intended to meet the following goals: stimulate technological innovation in the private sector; strengthen the role of small business in meeting Federal research or research and development (R/R&D) needs; increase the commercial application of Federally-supported research results; foster and encourage participation by socially and economically disadvantaged small business concerns and women-owned business concerns in the SBIR program; and improve the return on investment from Federally-funded research for economic and social benefits to the Nation.

NIAAA and the Division of Treatment and Recovery Research are seeking to expand our portfolio to address these needs and to advance five main areas in health services research. These five areas include accessibility, increased treatment appeal, costs, dissemination and implementation, and health disparities. We are particularly interested in applications addressing the interaction between one or more of these five areas and those using study designs extending beyond standard randomized clinical trials, e.g., effectiveness-implementation hybrid, Sequential Multiple Assignment Randomized Trial (SMART), and multiphase optimization study (MOST), and studies proposing culturally-informed adaptations of existing evidence-based interventions.